# Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

> **NCT01154153** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 140 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial and/or Seasonal

## Interventions

- **DRUG:** Placebo nasal spray
- **DRUG:** Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)
- **DRUG:** Placebo nasal spray
- **DRUG:** Claritin® Syrup

## Key facts

- **NCT ID:** NCT01154153
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2012-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154153, "Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01154153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*